To the editor:
Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia
Hairy cell leukemia (HCL) shows distinct clinicopathologic, immunophenotypic, and gene expression features. [1] [2] [3] We previously identified the BRAF-V600E mutation as the disease-defining genetic event in HCL. 4 This mutation is present in virtually all cases of HCL but rarely in other B-cell lymphomas, remains stable over time (being consistently detectable at relapse), and leads to the constitutive activation of the mitogen-activated protein kinase (MAPK) pathway 4 that is potentially druggable with BRAF-V600E inhibitors. These findings have been confirmed in 2 studies recently published in this journal. 5, 6 Functional assays in HCL have been hampered by the scarcity of leukemic cells available for analysis because of frequent shows the absence of the T-to-A point mutation at codon 600 leading to the V600E amino acid replacement, which is instead present heterozygously in primary leukemic cells MACS-purified from the peripheral blood of an HCL patient (left chromatogram). Both HC-1 cells and patient's leukemic cells display a wild-type codon 594 (GAT), as opposed to HAIR-M cells harboring a clonal heterozygous T-to-A point mutation at this codon (not shown) that leads to the D594E amino acid replacement. HC-1 cells xenografted in an NSG mouse show diffuse infiltration of the spleen by large B-cell lymphoma-like cells (right H&E staining) that are negative for annexin-1 (ANXA1; right ANXA1 immunostaining 1 ). Conversely, the splenectomy specimen of the HCL patient is infiltrated by small mature-looking lymphoid cells with wide pale cytoplasm (left H&E staining) strongly expressing annexin-1 (left ANXA1-staining). All micrographs were collected using an Olympus B61 microscope (equipped with an Olympus UPlanApo 40ϫ/0.8 NA objective and with an Olympus E330-ADU1.2x camera) and were acquired and processed using Olympus cell^B imaging software.
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For personal use only. on November 7, 2017. by guest www.bloodjournal.org From pancytopenia and/or punctio sicca at marrow aspiration. Moreover, no animal models of HCL are available. 3 To overcome these problems, cell lines have been established from HCL patients [7] [8] [9] [10] and used for functional studies. However, there is no definitive evidence that they are of authentic HCL origin.
To clarify this issue, we searched for BRAF-V600E (the genetic hallmark of HCL) in the human HCL cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ). None of them carried BRAF-V600E (Figure 1) . However, HAIR-M carried a clonal heterozygous T-to-A transversion at position 1782 of the BRAF coding sequence (not shown), leading to the replacement of aspartic acid with glutammic acid (D594E). This variant has been previously reported in only 1 case (a primary cutaneous melanoma 11 ) of Ͼ 19 000 BRAF-mutated cancer samples listed in COSMIC-v56 (Catalog of Somatic Mutations In Cancer). Although this missense variant (D594E) is not described as a germ line polymorphism in single-nucleotide polymorphism (SNP) databases (dbSNP135 and 1000-genomes), its somatic origin in that melanoma patient was not evaluated. 11 Thus the functional consequences of BRAF-D594E in the HAIR-M cell line remain unclear. Taken together, these results cast doubts on the HCL origin of the BONNA-12, ESKOL, HAIR-M, and HC-1 cell lines. Doubts were also reinforced by the morphologic appearance of these cell lines (similar to lymphoblastoid cells), their EBVpositivity (except for HAIR-M), [7] [8] [9] [10] and their lack of the typical HCL immunophenotype (coexpression of annexin-1/CD25/CD11c/ CD103; not shown). Similarly, ESKOL and HC-1 cells xenotransplanted in severely immunodeficient NSG mice showed the morphology of diffuse large B-cell lymphoma and were annexin-1 negative (Figure 1 ).
Because these cell lines do not represent a reliable HCL model either in vitro or in vivo, we sought to engraft in NSG mice MACS-purified (Ͼ 90% pure) patients' hairy cells. No engraftment was observed in a mouse that was injected intravenously with 3.8 million HCL cells and died 1 year later. Engraftment was not achieved even in another mouse that died 10 months after injection of 15 million leukemic cells from a different HCL patient harboring a hemizygous/homozygous BRAF-V600E mutation and presenting with markedly high hairy cell count (WBC 39000/mmc). Conversely, as few as 1.2 million ESKOL cells and 0.98 million HC-1 cells were enough to kill the animals as early as 3 weeks after intravenous injection. These results suggest that primary HCL cells appear difficult to engraft even in NSG mice.
Altogether our findings call for the development of conditional knock-in mice expressing BRAF-V600E in specific mature B-cell subsets as appropriate models for studying HCL.
